Selective killing of Klebsiella pneumoniae by 5-trifluoromethylthioribose: Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase

Alan J. Gianotti, Paula A. Tower, John H. Sheley, Paul A. Conte, Craig Spiro, Adolph J. Ferro, John H. Fitchen, Michael Riscoe

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

5′-Deoxy-5′-methylthioadenosine (MTA), an important intermediate in methionine recycling, can be metabolized by one of two mechanisms that appear to be mutually exclusive. In human cells, MTA is degraded in one step to adenine and 5-methylthioribose 1-phosphate (MTR-1-P) via MTA phosphorylase. In contrast, certain microbes metabolize MTA in two steps: first to 5-methylthioribose (MTR) followed by conversion to MTR-1-P. The enzymes involved in this two-step conversion are MTA nucleosidase and MTR kinase. In both cases, MTR-1-P is subsequently recycled to methionine. Because MTR kinase is "unique" to microbes (it is also found in plant tissue) and since it is essential to microbial methionine salvage, we hypothesized that MTR kinase is a promising target for chemotherapeutic exploitation. We demonstrate that 5-trifluoromethylthioribose (TFMTR), a structural analog of MTR, is a potent inhibitor of the MTR kinase-containing organism Klebsiella pneumoniae. TFMTR not only inhibits the growth of K. pneumoniae in a dose-dependent manner (50% inhibition at ∼40 nM) but also competitively inhibits MTR kinase activity (Ki ∼ 7 μM). Furthermore, TFMTR is shown to be a substrate for MTR kinase (Km = 1.7 μM), suggesting that the drug could be converted to toxic products (e.g. trifluoromethionine or carbonothionic difluoride) in enzyme-containing organisms. Structural analogs of MTR represent a new class of compounds with the potential for treating diseases caused by MTR kinase-containing microorganisms.

Original languageEnglish (US)
Pages (from-to)831-837
Number of pages7
JournalJournal of Biological Chemistry
Volume265
Issue number2
StatePublished - Jan 15 1990
Externally publishedYes

Fingerprint

Klebsiella pneumoniae
Phosphotransferases
Enzymes
Methionine
Poisons
Salvaging
Recycling
Adenine
5-trifluoromethylthioribose
5-methylthioribose kinase
Microorganisms
Cells
Tissue
5'-methylthioadenosine
Growth
Pharmaceutical Preparations
Substrates

ASJC Scopus subject areas

  • Biochemistry

Cite this

Selective killing of Klebsiella pneumoniae by 5-trifluoromethylthioribose : Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase. / Gianotti, Alan J.; Tower, Paula A.; Sheley, John H.; Conte, Paul A.; Spiro, Craig; Ferro, Adolph J.; Fitchen, John H.; Riscoe, Michael.

In: Journal of Biological Chemistry, Vol. 265, No. 2, 15.01.1990, p. 831-837.

Research output: Contribution to journalArticle

Gianotti, Alan J. ; Tower, Paula A. ; Sheley, John H. ; Conte, Paul A. ; Spiro, Craig ; Ferro, Adolph J. ; Fitchen, John H. ; Riscoe, Michael. / Selective killing of Klebsiella pneumoniae by 5-trifluoromethylthioribose : Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase. In: Journal of Biological Chemistry. 1990 ; Vol. 265, No. 2. pp. 831-837.
@article{136a022c9e9940648a833e1e7c5418d2,
title = "Selective killing of Klebsiella pneumoniae by 5-trifluoromethylthioribose: Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase",
abstract = "5′-Deoxy-5′-methylthioadenosine (MTA), an important intermediate in methionine recycling, can be metabolized by one of two mechanisms that appear to be mutually exclusive. In human cells, MTA is degraded in one step to adenine and 5-methylthioribose 1-phosphate (MTR-1-P) via MTA phosphorylase. In contrast, certain microbes metabolize MTA in two steps: first to 5-methylthioribose (MTR) followed by conversion to MTR-1-P. The enzymes involved in this two-step conversion are MTA nucleosidase and MTR kinase. In both cases, MTR-1-P is subsequently recycled to methionine. Because MTR kinase is {"}unique{"} to microbes (it is also found in plant tissue) and since it is essential to microbial methionine salvage, we hypothesized that MTR kinase is a promising target for chemotherapeutic exploitation. We demonstrate that 5-trifluoromethylthioribose (TFMTR), a structural analog of MTR, is a potent inhibitor of the MTR kinase-containing organism Klebsiella pneumoniae. TFMTR not only inhibits the growth of K. pneumoniae in a dose-dependent manner (50{\%} inhibition at ∼40 nM) but also competitively inhibits MTR kinase activity (Ki ∼ 7 μM). Furthermore, TFMTR is shown to be a substrate for MTR kinase (Km = 1.7 μM), suggesting that the drug could be converted to toxic products (e.g. trifluoromethionine or carbonothionic difluoride) in enzyme-containing organisms. Structural analogs of MTR represent a new class of compounds with the potential for treating diseases caused by MTR kinase-containing microorganisms.",
author = "Gianotti, {Alan J.} and Tower, {Paula A.} and Sheley, {John H.} and Conte, {Paul A.} and Craig Spiro and Ferro, {Adolph J.} and Fitchen, {John H.} and Michael Riscoe",
year = "1990",
month = "1",
day = "15",
language = "English (US)",
volume = "265",
pages = "831--837",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "2",

}

TY - JOUR

T1 - Selective killing of Klebsiella pneumoniae by 5-trifluoromethylthioribose

T2 - Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase

AU - Gianotti, Alan J.

AU - Tower, Paula A.

AU - Sheley, John H.

AU - Conte, Paul A.

AU - Spiro, Craig

AU - Ferro, Adolph J.

AU - Fitchen, John H.

AU - Riscoe, Michael

PY - 1990/1/15

Y1 - 1990/1/15

N2 - 5′-Deoxy-5′-methylthioadenosine (MTA), an important intermediate in methionine recycling, can be metabolized by one of two mechanisms that appear to be mutually exclusive. In human cells, MTA is degraded in one step to adenine and 5-methylthioribose 1-phosphate (MTR-1-P) via MTA phosphorylase. In contrast, certain microbes metabolize MTA in two steps: first to 5-methylthioribose (MTR) followed by conversion to MTR-1-P. The enzymes involved in this two-step conversion are MTA nucleosidase and MTR kinase. In both cases, MTR-1-P is subsequently recycled to methionine. Because MTR kinase is "unique" to microbes (it is also found in plant tissue) and since it is essential to microbial methionine salvage, we hypothesized that MTR kinase is a promising target for chemotherapeutic exploitation. We demonstrate that 5-trifluoromethylthioribose (TFMTR), a structural analog of MTR, is a potent inhibitor of the MTR kinase-containing organism Klebsiella pneumoniae. TFMTR not only inhibits the growth of K. pneumoniae in a dose-dependent manner (50% inhibition at ∼40 nM) but also competitively inhibits MTR kinase activity (Ki ∼ 7 μM). Furthermore, TFMTR is shown to be a substrate for MTR kinase (Km = 1.7 μM), suggesting that the drug could be converted to toxic products (e.g. trifluoromethionine or carbonothionic difluoride) in enzyme-containing organisms. Structural analogs of MTR represent a new class of compounds with the potential for treating diseases caused by MTR kinase-containing microorganisms.

AB - 5′-Deoxy-5′-methylthioadenosine (MTA), an important intermediate in methionine recycling, can be metabolized by one of two mechanisms that appear to be mutually exclusive. In human cells, MTA is degraded in one step to adenine and 5-methylthioribose 1-phosphate (MTR-1-P) via MTA phosphorylase. In contrast, certain microbes metabolize MTA in two steps: first to 5-methylthioribose (MTR) followed by conversion to MTR-1-P. The enzymes involved in this two-step conversion are MTA nucleosidase and MTR kinase. In both cases, MTR-1-P is subsequently recycled to methionine. Because MTR kinase is "unique" to microbes (it is also found in plant tissue) and since it is essential to microbial methionine salvage, we hypothesized that MTR kinase is a promising target for chemotherapeutic exploitation. We demonstrate that 5-trifluoromethylthioribose (TFMTR), a structural analog of MTR, is a potent inhibitor of the MTR kinase-containing organism Klebsiella pneumoniae. TFMTR not only inhibits the growth of K. pneumoniae in a dose-dependent manner (50% inhibition at ∼40 nM) but also competitively inhibits MTR kinase activity (Ki ∼ 7 μM). Furthermore, TFMTR is shown to be a substrate for MTR kinase (Km = 1.7 μM), suggesting that the drug could be converted to toxic products (e.g. trifluoromethionine or carbonothionic difluoride) in enzyme-containing organisms. Structural analogs of MTR represent a new class of compounds with the potential for treating diseases caused by MTR kinase-containing microorganisms.

UR - http://www.scopus.com/inward/record.url?scp=0025099504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025099504&partnerID=8YFLogxK

M3 - Article

C2 - 2153115

AN - SCOPUS:0025099504

VL - 265

SP - 831

EP - 837

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 2

ER -